Table 3.

Change from baseline for the Connors Adult Attention Deficit/Hyperactivity Disorder Rating Scale, short form (CAARS)

CAARS item	Treatment groupa
	Atomoxetine			Placebo
	No.	Mean ± SD	95% CI	No.	Mean ± SD	95% CI
Change from baseline to 2 weeks
Inattention	14	−0.6 ± 9.6	−6.1, 5.0	14	0.8 ± 6.1	−2.7, 4.3
Hyperactivity	14	−1.4 ± 9.7	−7.0, 4.2	14	−1.3 ± 6.3	−4.9, 2.4
Impulsivity	14	−0.9 ± 11.9	−7.8, 5.9	14	−1.9 ± 6.9	−5.9, 2.1
Problems with self‐concept	14	1.1 ± 10.6	−5.0, 7.3	14	0.5 ± 6.5	−3.3, 4.3
ADHD index	14	−1.3 ± 11.0	−7.7, 5.1	14	−0.4 ± 4.5	−3.0, 2.2
Change from baseline to 10 weeks
Inattention	11	−5.7 ± 7.9	−11.0, −0.4	14	−1.6 ± 3.9	−3.9, 0.6
Hyperactivity	11	−2.4 ± 8.2	−7.9, 3.1	14	−1.1 ± 7.1	−5.2, 3.0
Impulsivity	11	−5.4 ± 7.4	−10.4, −0.4	14	−0.6 ± 5.7	−3.9, 2.6
Problems with self‐concept	11	−0.8 ± 9.9	−7.5, 5.8	14	−3.1 ± 8.2	−7.9, 1.6
ADHD index	11	−4.9 ± 9.7	−11.4, 1.6	14	−1.7 ± 7.7	−6.2, 2.7

SD, standard deviation; CI, confidence interval; ADHD, attention deficit/hyperactivity disorder.

^aValues reflect changes in T‐scores (mean ± SD, 50 ± 10) after demographic correction according to the test manual.